Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The benefit of VEN-based therapy in patients who have newly diagnosed AML with mutations in the TP53 gene (TP53^mut) over standard therapy is undefined.

中文翻译：

---

新诊断的 TP53 突变急性髓细胞白血病患者的结果，无论是否接受基于 venetoclax 的治疗

Venetoclax (VEN) 与低甲基化剂 (HMA) 联用已成为 75 岁以上患者和新诊断为急性髓性白血病 (AML) 且不适合接受强化化疗的患者的护理标准。对于新诊断为TP53基因 ( TP53 ^mut )突变的 AML 患者，基于 VEN 的治疗相对于标准治疗的益处尚未确定。